Fannie Mae, Freddie Mac shares tumble after conservatorship comments
CARY, N.C. - Heron Therapeutics, Inc. (NASDAQ:HRTX) saw its stock surge 21% after the commercial-stage biotechnology company reported better-than-expected fourth quarter earnings and revenue, while also providing strong guidance for 2025.
Heron posted adjusted earnings per share of $0.02 for Q4 2024, beating analyst estimates of -$0.03. Revenue for the quarter came in at $40.78 million, surpassing the consensus estimate of $37.3 million and representing a 19.1% increase YoY.
The company’s ZYNRELEF pain medication generated Q4 net revenue of $8.5 million, up 48.5% YoY. Total (EPA:TTEF) net revenue for 2024 reached $144.2 million, a 13.6% increase from the previous year.
"2024 was a milestone year for Heron. We delivered strong financial results, including positive Net Income for Q4 2024, achieved our operational objectives, and repositioned the business for future growth," said CEO Craig Collard.
Looking ahead, Heron provided 2025 full-year net revenue guidance of $153 million to $163 million, compared to analyst expectations of $160.6 million. The company also projects adjusted EBITDA of $0 to $8 million for the year.
Heron highlighted several positive developments, including expanded label indications for ZYNRELEF and the launch of a new vial access needle in December 2024. The company ended the year with $59.3 million in cash and short-term investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.